DEVELOPMENT OF A STROKE PATHWAY PHARMACY TEAM TO SUPPORT REABLEMENT AND MEDICATION OPTIMISATION
CP-087
USE AND EFFECTIVENESS OF PALIVIZUMAB FOR IMMUNOPROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS
CP-234
ANTIMICROBIAL STEWARDSHIPS: SEMI-AUTOMATIC VALIDATION TOOL FOR ANTIMICROBIAL PRESCRIBING BASED ON REAL TIME ANTIBIOGRAMS
CP-233
EFFECTIVENESS OF REGORAFENIB IN THE TREATMENT OF METASTATIC COLORECTAL CANCER IN SELECTED PATIENTS
CP-232
METASTATIC PANCREATIC CANCER TREATMENT WITH NAB-PACLITAXEL: EFFECTIVENESS AND SAFETY
CP-231
EFFICACY PROFILE OF DIRECT ACTING ANTIVIRAL BASED THERAPY IN HCV MONO AND CO-INFECTED PATIENTS IN A REAL WORLD SETTING
CP-230
HEALTH TECHNOLOGY ASSESSMENT: CHOICE BETWEEN CYTOTOXIC SAFETY CABINETS AND ISOLATORS FOR CYTOTOXIC DRUG RECONSTITUTION
CP-229
IS THERE AN ADDED VALUE CONTRIBUTION OF BIOLOGICAL GLUE IN SURGERY OF CYANOTIC CONGENITAL HEART DISEASES?
CP-227
RISK MINIMISATION OF ADVERSE DRUG REACTIONS: ROLE OF THE PHARMACIST
CP-226
SAFETY OF DIRECT ACTING ANTIVIRAL AND ANTIRETROVIRALS DRUGS IN HCV PATIENTS COINFECTED WITH HIV-1: CLINICAL PRACTICE EXPERIENCE
CP-225
KERION CELSI: AN INFECTION WITH TRICHOPHYTUN VERRUCOSUM. A CASE REPORT
CP-224
EVALUATION OF TWO CATHETER LOCKING SOLUTIONS IN HAEMODIALYSIS PATIENTS
CP-223
EFFECTIVENESS AND SAFETY USING ERIBULIN IN METASTATIC BREAST CANCER
CP-219
EFFECTIVENESS AND SAFETY OF SWITCHING TO DUAL ANTIRETROVIRAL THERAPY IN A TREATMENT EXPERIENCED HIV COHORT
CP-217
EVALUATION OF EFFICACY, EFFICIENCY AND PERSISTENCE RATE OF BIOLOGICAL THERAPY IN THE TREATMENT OF MODERATE TO SEVERE PSORIASIS IN A THIRD LEVEL REFERENCE HOSPITAL
